EICHOR

Recruiting studies: Relapsed Or Refractory Hematologic Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Parti
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07138209 CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147 A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase 1 · 4 location(s) · NovaOnco Therapeutics Co., Ltd. · NCT06820268 Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661 SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurren
Phase 1 · 4 location(s) · Uma Borate · NCT06222580 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity
Phase 1/Phase 2 · 3 location(s) · Advanced BioDesign · NCT05601726 Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Ref
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04774393 CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/Phase 2 · 4 location(s) · Beijing GoBroad Hospital · NCT06316856 A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Phase 1 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07173595 Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322 Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839 Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461 CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012 Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refracto
Phase 1/Phase 2 · 1 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT06484829 Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/Phase 2 · 12 location(s) · Ascentage Pharma Group Inc. · NCT04501120 ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02392572 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 · 8 location(s) · FBD Biologics Limited · NCT05892718 Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456 A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07609030 Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853 Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Minsk Scientific-Practical Center for Surgery, Transplantati · NCT07477912 Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT06376721 Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory A
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04047641 Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed
Phase 2 · 1 location(s) · Naresh Bumma · NCT07657312 A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06066203 CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR
NA · 1 location(s) · Beijing GoBroad Hospital · NCT06389305 CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT07347418 A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171 A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532268 Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase 1 · 2 location(s) · Vanderbilt-Ingram Cancer Center · NCT06399640

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →